Cboe UK CHF

Basilea Pharmaceutica AG (BSLNZ.XC)

43.85
-0.50
(-1.13%)
As of 2:30:43 PM GMT+1. Market Open.
Currency in CHF All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
208,543
208,543
157,634
147,765
148,122
Cost of Revenue
38,681
38,681
26,794
24,603
24,072
Gross Profit
169,862
169,862
130,840
123,162
124,050
Operating Expense
108,685
108,685
111,635
104,619
122,878
Operating Income
61,177
61,177
19,205
18,543
1,172
Net Non Operating Interest Income Expense
-2,928
-2,928
-9,512
-9,522
-8,085
Pretax Income
60,260
60,260
10,461
12,102
-6,794
Tax Provision
-17,333
-17,333
10
-45
37
Net Income Common Stockholders
77,593
77,593
10,451
12,147
-6,831
Diluted NI Available to Com Stockholders
77,593
77,593
10,451
12,147
-6,831
Basic EPS
6.42
6.42
0.87
1.02
-0.58
Diluted EPS
5.83
5.83
0.86
1.02
-0.58
Basic Average Shares
12,089.67
12,089.67
11,991.39
11,860.96
11,681.98
Diluted Average Shares
13,855.04
13,855.04
12,143.08
11,943.53
11,681.98
Total Operating Income as Reported
61,177
61,177
19,205
18,543
1,187
Total Expenses
147,366
147,366
138,429
129,222
146,950
Net Income from Continuing & Discontinued Operation
77,593
77,593
10,451
12,147
-6,831
Normalized Income
77,593
77,593
10,451
12,147
-6,351.41
Interest Income
1,416
1,416
1,690
326
66
Interest Expense
4,344
4,344
11,202
9,848
8,151
Net Interest Income
-2,928
-2,928
-9,512
-9,522
-8,085
EBIT
64,604
64,604
21,663
21,950
1,357
EBITDA
66,336
66,336
23,240
23,047
2,111
Reconciled Cost of Revenue
38,681
38,681
26,794
24,603
24,072
Reconciled Depreciation
1,732
1,732
1,577
1,097
754
Net Income from Continuing Operation Net Minority Interest
77,593
77,593
10,451
12,147
-6,831
Total Unusual Items Excluding Goodwill
--
--
--
-41
-482
Total Unusual Items
--
--
--
-41
-482
Normalized EBITDA
66,336
66,336
23,240
23,047
2,593
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
-2.41
12/31/2021 - 11/24/2009

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade